These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28082342)

  • 1. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
    Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
    Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.
    Fu S; Wang M; Zhao H; Li R; Lairson DR; Giordano SH; Zhao B; Du XL
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e616-e623. PubMed ID: 31563564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.
    Bond DA; Huang Y; Ruppert AS; Walker AR; Dotson EK; Roddy J; Blum KA; Christian BA
    Leuk Lymphoma; 2017 Jul; 58(7):1589-1597. PubMed ID: 27838951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.
    Kamdar M; Li H; Chen RW; Rimsza LM; Leblanc ML; Fenske TS; Shea TC; Barr PM; Phillips TJ; Leonard JP; Kahl BS; Friedberg JW; Smith SM
    Blood Adv; 2019 Oct; 3(20):3132-3135. PubMed ID: 31648328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
    Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
    Chong EA; Ahmadi T; Aqui NA; Svoboda J; Nasta SD; Mato AR; Walsh KM; Schuster SJ
    Clin Cancer Res; 2015 Apr; 21(8):1835-42. PubMed ID: 25632047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma.
    Lamm W; Kiesewetter B; Puhr H; Dolak W; Mayerhöfer ME; Raderer M
    Ann Hematol; 2019 Jun; 98(6):1519-1520. PubMed ID: 30547188
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of
    Eskelund CW; Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Pedersen LB; Geisler CH; Jerkeman M; Grønbæk K
    Haematologica; 2018 Nov; 103(11):e541-e543. PubMed ID: 29794145
    [No Abstract]   [Full Text] [Related]  

  • 11. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
    Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Grønbæk K; Sundberg J; Pedersen LB; Ralfkiær E; Karjalainen-Lindsberg ML; Sundström C; Ehinger M; Geisler C; Jerkeman M
    Blood; 2016 Oct; 128(14):1814-1820. PubMed ID: 27354719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
    Hitz F; Zucca E; Pabst T; Fischer N; Cairoli A; Samaras P; Caspar CB; Mach N; Krasniqi F; Schmidt A; Rothermundt C; Enoiu M; Eckhardt K; Berardi Vilei S; Rondeau S; Mey U
    Br J Haematol; 2016 Jul; 174(2):255-63. PubMed ID: 27018242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rare composite lymphoma: follicular and in situ mantle cell.
    Marí-Jimenez P; Martínez-Losada C; Centeno-Haro M; Rodríguez-García G; Perez-Seoane C; Sánchez-García J
    Ann Hematol; 2016 Aug; 95(8):1351-2. PubMed ID: 27103006
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
    Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
    N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
    Sacchi S; Marcheselli R; Bari A; Buda G; Molinari AL; Baldini L; Vallisa D; Cesaretti M; Musto P; Ronconi S; Specchia G; Silvestris F; Guardigni L; Ferrari A; Chiapella A; Carella AM; Santoro A; Di Raimondo F; Marcheselli L; Pozzi S
    Haematologica; 2016 May; 101(5):e196-9. PubMed ID: 26858355
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Front-line and second-line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis.
    Harmanen M; Sorigue M; Khan M; Prusila R; Klaavuniemi T; Kari E; Jantunen E; Sunela K; Rajamäki A; Alanne E; Kuitunen H; Jukkola A; Sancho JM; Kuittinen O; Rönkä A
    Eur J Haematol; 2024 Aug; 113(2):218-226. PubMed ID: 38661269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the
    Storti S; Spina M; Pesce EA; Salvi F; Merli M; Ruffini A; Cabras G; Chiappella A; Angelucci E; Fabbri A; Liberati AM; Tani M; Musuraca G; Molinari A; Petrilli MP; Palladino C; Ciancia R; Ferrario A; Gasbarrino C; Monaco F; Fraticelli V; De Vellis A; Merli F; Luminari S
    Haematologica; 2018 Aug; 103(8):1345-1350. PubMed ID: 29748444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
    Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
    Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.